<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37126792</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-7385</ISSN><JournalIssue CitedMedium="Internet"><Volume>102</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>American journal of physical medicine &amp; rehabilitation</Title><ISOAbbreviation>Am J Phys Med Rehabil</ISOAbbreviation></Journal><ArticleTitle>What Are the Effects of Treatments for Sialorrhea in People With Motor Neuron Disease/Amyotrophic Lateral Sclerosis?: A Cochrane Review Summary With Commentary.</ArticleTitle><Pagination><StartPage>926</StartPage><EndPage>928</EndPage><MedlinePgn>926-928</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PHM.0000000000002272</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Del Furia</LastName><ForeName>Matteo Johann</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>From the IRCCS Istituto Ortopedico Galeazzi, Milan, Italy (MJDF); and Department of Biomedical, Surgical and Dental Sciences, University "La Statale," Milan, Italy (IB).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Battel</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Phys Med Rehabil</MedlineTA><NlmUniqueID>8803677</NlmUniqueID><ISSNLinking>0894-9115</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Cochrane Database Syst Rev. 2022 May 20;5:CD006981</RefSource><PMID Version="1">35593746</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012798" MajorTopicYN="Y">Sialorrhea</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Financial disclosure statements have been obtained, and no conflicts of interest have been reported by the authors or by any individuals in control of the content of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37126792</ArticleId><ArticleId IdType="doi">10.1097/PHM.0000000000002272</ArticleId><ArticleId IdType="pii">00002060-990000000-00246</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>James E, Ellis C, Brassington R, et al.: Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane Database Sys Rev 2022;5:CD006981</Citation></Reference><Reference><Citation>Van Es MA, Hardiman O, Chio A, et al.: Amyotrophic lateral sclerosis. Lancet 2017;390:2084&#x2013;98</Citation></Reference><Reference><Citation>Simonds AK: Progress in respiratory management of bulbar complications of motor neuron disease/amyotrophic lateral sclerosis? Thorax 2017;72:199&#x2013;201</Citation></Reference><Reference><Citation>Morgante F, Bavikatte G, Anwar F, et al.: The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin&#xae;). Ther Adv Neurol Disord 2019;12:1756286419888601</Citation></Reference><Reference><Citation>Garuti G, Rao F, Ribuffo V, et al.: Sialorrhea in patients with ALS: current treatment options. Degener Neurol Neuromuscul Dis 2019;9:19&#x2013;26</Citation></Reference><Reference><Citation>Lazovic M, Nikolic D, Boyer FC, et al.: Evidence-based position paper on physical and rehabilitation medicine practice for people with amyotrophic lateral sclerosis. Eur J Phys Rehabil Med 2022;58:271&#x2013;9</Citation></Reference><Reference><Citation>Negrini S, Selb M, Kiekens C, et al.: 3rd Cochrane rehabilitation methodology meeting participants. Rehabilitation definition for research purposes. A global stakeholders' initiative by Cochrane rehabilitation. Eur J Phys Rehabil Med 2022;58:333&#x2013;41</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>